Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. Relative to other triptans, frovatriptan has a long half-life (26 h) and a low incidence of migraine recurrence (17%). Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a relatively good safety and tolerability profile. Recent studies have also shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual period significantly reduced the incidence and severity of menstrual migraine (MM; attacks that regularly start day -2 to +3 relative to menses). Prevention may be important because MM attacks have been characterized as being of longer duration, more severe and more refractory to treatment than non-MM attacks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737175.8.5.723 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Kidney Injury Following Cardiac Surgery: A Review of Our Current Understanding.
Am J Cardiovasc Drugs
January 2025
Pediatric Nephrology, State University of Campinas, São Paulo, Brazil.
Around one-quarter of all patients undergoing cardiac procedures, particularly those on cardiopulmonary bypass, develop cardiac surgery-associated acute kidney injury (CSA-AKI). This complication increases the risk of several serious morbidities and of mortality, representing a significant burden for both patients and the healthcare system. Patients with diminished kidney function before surgery, such as those with chronic kidney disease, are at heightened risk of developing CSA-AKI and have poorer outcomes than patients without preexisting kidney injury who develop CSA-AKI.
View Article and Find Full Text PDFAtropine plus omeprazole for acute gastritis: Efficacy and safety analysis.
Pak J Pharm Sci
January 2025
Jian'ou Municipal Hospital, Nanping, Fujian, China.
This article primarily discusses the efficacy and safety of atropine (ATR) plus omeprazole (OME) for the treatment of acute gastritis (AG). From May 2022 to May 2024, 95 AG patients were selected, including 50 cases treated with ATR+OME (observation group) and 45 cases with anisodamine (ADM) plus OME (control group). Comparative analyses of the following dimensions were then carried out: Clinical efficacy, safety (xerostomia, palpitations and headaches), symptom remission time (stomach pain, abdominal distension and nausea and vomiting), serum inflammatory factors (tumor necrosis factor [TNF]-α, interleukin [IL]-6 and interferon [IFN]-β) and plasma gastrointestinal hormones (epidermal growth factor [EGF], gastrin [GAS] and somatostatin [SS]).
View Article and Find Full Text PDFDeveloping a decision support tool to predict delayed discharge from hospitals using machine learning.
BMC Health Serv Res
January 2025
Department of Industrial Engineering, Dalhousie University, PO Box 15000, Halifax, B3H 4R2, NS, Canada.
Background: The growing demand for healthcare services challenges patient flow management in health systems. Alternative Level of Care (ALC) patients who no longer need acute care yet face discharge barriers contribute to prolonged stays and hospital overcrowding. Predicting these patients at admission allows for better resource planning, reducing bottlenecks, and improving flow.
View Article and Find Full Text PDFA PDMS/chitosan/MPMs composite film based on multi-field coupling enhancement for African swine fever virus P72 protein detection.
Mikrochim Acta
January 2025
Shanxi Key Laboratory of Micro Nano Sensors & Artificial Intelligence Perception, College of Integrated Circuits, Taiyuan University of Technology, Taiyuan, 030024, China.
African swine fever (ASF) is an acute hemorrhagic disease in pigs caused by the African swine fever virus (ASFV), which has a high mortality rate and brought great damage to global pig farming industry. At present, there is no effective treatment or vaccine to combat ASFV infection, so early detection of ASFV has become particularly important. Therefore, the PDMS/chitosan/MPMs composite film was proposed to detect ASFV P72.
View Article and Find Full Text PDFComparison of the safety and efficacy of dual antiplatelet therapy versus tenecteplase in patients with minor nondisabling acute ischemic stroke.
Sci Rep
January 2025
Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
To evaluate the safety and efficacy of dual antiplatelet therapy (DAPT) versus tenecteplase in minor non-disabling acute ischemic stroke. This retrospective observational study utilized data from our stroke database. All consecutive patients with minor non-disabling acute ischemic stroke treated with either DAPT or tenecteplase between January 2020 and June 2023 were included in the analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!